Technical Analysis for KSPHF - Kissei Pharmaceuticals CO Ltd

Grade Last Price % Change Price Change
D 21.2 3.06% 0.6300
KSPHF closed up 3.06 percent on Friday, May 7, 2021, on 1.88 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat
Historical KSPHF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Hot IPO Pullback Bullish Swing Setup 3.06%
Narrow Range Bar Range Contraction 3.06%
Gapped Down Weakness 3.06%
Fell Below 20 DMA Bearish 0.47%
Hot IPO Pullback Bullish Swing Setup 0.47%
Narrow Range Bar Range Contraction 0.47%
Gapped Down Weakness 0.47%
Volume Surge Other -4.50%
Older End-of-Day Signals for KSPHF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kissei Pharmaceuticals CO Ltd Description

Kissei Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast and Glubes tablets for diabetes; Epoetin Alfa BS injection for the treatment of renal anemia; P-TOL chewable tablets for treating hyperphosphatemia in patients on dialysis; Mitiglinide for treating Type 2 diabetes mellitus; and RECTABUL, a rectal foam product for the treatment of ulcerative colitis. The company's product pipeline includes KPS-0373 that is in Phase III clinical trial to treat spinocerebellar ataxia; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; YS110, which is in Phase I/II clinical trial for the treatment of Malignant mesothelioma; and JR-131 that is in NDA preparation for renal anemia. It is also developing KLH-2109, which is in Phase II clinical trial for treating endometriosis and uterine fibroids in Japan and Phase III clinical trial worldwide; KDT-3594 that is in Phase II clinical trial for the treatment of Parkinson's disease; MR13A9 that is in Phase II clinical trial to treat uremic pruritus in dialysis patients; and CCX168, which is in Phase III clinical trial for the treatment of anti-neutrophil cytoplasmic auto-antibody associated vasculitis. In addition, the company is developing Bedoradrine that is in Phase II clinical trial for the treatment of acute exacerbation of asthma, as well as provides information solution and construction subcontracting services. Additionally, it develops and sells protein controlled and energy supply foods. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was founded in 1946 and is headquartered in Matsumoto, Japan.


Classification

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Keywords: Medicine Health Medical Specialties Pharmaceutical Industry Diabetes Pharmaceutical Products Parkinson's Disease Asthma Ulcer Dialysis Taxi Contracting Services Cx Axia Clinical Trial Energy Supply Alfa Type 2 Diabetes Anemia Diabetes Mellitus Treatment Of Parkinson's Disease Lube Bella Colitis Ulcerative Colitis Pruritus Fibroids Poet Silodosin Uterine Fibroid Uterine Fibroids Cerbat Endometriosis Epoetin Alfa Exacerbation Hyperphosphatemia Mesothelioma

Is KSPHF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 25.5
52 Week Low 19.7
Average Volume 426
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 21.5115
10-Day Moving Average 21.2640
Average True Range 0.7597
ADX 14.29
+DI 44.3896
-DI 55.6123
Chandelier Exit (Long, 3 ATRs ) 21.7209
Chandelier Exit (Short, 3 ATRs ) 21.9791
Upper Bollinger Band 23.5793
Lower Bollinger Band 19.4437
Percent B (%b) 0.42
BandWidth 19.2251
MACD Line -0.6515
MACD Signal Line -0.6649
MACD Histogram 0.0135
Fundamentals Value
Market Cap 990.38 Million
Num Shares 46.7 Million
EPS
Price-to-Sales 1.53
Price-to-Book 0.45
Dividend 0.52
Dividend Yield 2.45%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.2000
Resistance 3 (R3) 21.2000 21.2000 21.2000
Resistance 2 (R2) 21.2000 21.2000 21.2000 21.2000
Resistance 1 (R1) 21.2000 21.2000 21.2000 21.2000 21.2000
Pivot Point 21.2000 21.2000 21.2000 21.2000 21.2000
Support 1 (S1) 21.2000 21.2000 21.2000 21.2000 21.2000
Support 2 (S2) 21.2000 21.2000 21.2000 21.2000
Support 3 (S3) 21.2000 21.2000 21.2000
Support 4 (S4) 21.2000